The presence of FLT3 internal tandem dupulication (FLT3/ITD) in patients with acute myeloid leukemia (AML) with normal karyotype was investigated in order to evaluate its clinical and prognostic significance. Methods: The FLT3/ITD was studied by PCR assay in bone marrow samples obtained from 123 patients at diagnosis. Ninety patients who received intensive induction chemotherapy were evaluated. Results: Of total 123 patients, forty-seven (38.2%) demonstrated the aberrant FLT3/ITD. Patients with FLT3/ITD had significantly higher leukocyte counts at presentation than did patients without FLT3/ITD (P=0.04). By multivariate analysis, the FLT3/ITD was an independent prognostic factor of leukemic-free survival (LFS) (P=0.01) in AML patients with normal karyotype. Conclusion: This study demonstrated that the presence of the FLT3/ITD was a significant factor for poor prognosis in AML patients with normal karyotype. (Korean J Hematol 2007;42:250-257 .) Key Words: FLT3/ITD, Acute myeloid leukemia, Normal karyotype 250 접수：2007년 7월 27일, 수정：2007년 8월 31일 승인：2007년 9월 4일 교신저자：김형준, 전라남도 화순군 화순읍 일심리 160 519-809, 화순전남대학교병원 혈액종양내과
INTRODUCTION
The fms-like tyrosine kinase 3 (FLT3) belongs to the class III receptor tyrosine kinase (RTK) family, which also includes the KIT, FMS, and Platelet-derived growth factor (PDGF) receptors. FLT3 is expressed in early hematopoietic progenitors and its di-merization by FLT3 ligand (FL) induces growth control signals in normal hematopoiesis. The gene encoding FLT3 maps to chromosome band 13q12, 1, 2) and an internal tandem duplication (ITD) of the gene (FLT3/ITD) can be detected in 20%∼30% of young adults with acute myeloid leukemia (AML). 3, 4) The duplication involves a segment of the juxtamembrane (JM)-domain-coding sequence, which frequently in- volves exon 14 and, less commonly, intron 14 or exon 15, and is always in-frame. 5) In support of a potential role of this mutation in leukemogenesis, FLT3/ITD from AML patients has been shown to induce autonomous proliferation in cytokine-dependent cell lines. 6, 7) Nonetheless, controversy exists as to the prognostic significance of FLT3/ITD. Previous studies have suggested that the mutation is an independent prognostic factor in AML patients, 4, 8) but an association with poor outcome has not been established in highly heterogeneous patient populations, such as with respect to age, karyotype, and treatment regimens. Several studies have also shown that FLT3/ITD predicted a poor clinical outcome in AML patients with normal karyotype; 9, 10) but it is still a matter of debate as to whether the mutation plays an independent role in the prognosis of those patients.
11)
The primary objective of this study was to determine the prognostic influence of FLT3/ITD in AML patients with normal karyotype.
MATERIALS AND METHODS

Patients
Bone marrow (BM) samples from 123 adult AML patients at five different hospitals in Korea were used in this study and were retrospectively analyzed for the presence of FLT3/ITD by PCR on genomic DNA. The 123 patients had all been diagnosed with de novo AML with normal karyotype. Of the patients participating in the study, ninety patients received intensive induction chemotherapy and were included in the analysis of survival data. The details of the patients' age, gender, peripheral blood (PB) leukocyte counts, and percentages of BM blasts are given in Table 1 .
Treatment
Of the 90 patients, 40 (44.4%) patients received remission induction therapy consisting of 3 days of idarubicin (IDA) at 12mg/m 2 /day and 7 days of N 4behenoyl-1-D-arabinofuranosylcytosine (BH-AC) (300 mg/m 2 /day for patients younger than 40 years old, 200mg/m 2 /day for patients older than 40 years old). Thirty-three patients (36.7%) received 3 days of IDA at 12mg/m 2 /day and 7 days of cytarabine (Ara-C) at 100mg/m 2 /day. Etoposide, 6-thioguanine, or G-CSF was added to the treatment protocols for the remaining patients. If patients failed to achieve complete remission (CR) after the first round of induction chemotherapy, they received reinduction chemotherapy with same regimen. Patients achieving CR received three to four courses of combination chemotherapy or two to three courses of high-dose Ara-C chemotherapy for consolidation. Patients achieving CR were allowed to proceed to allogeneic or autologous stem cell transplantation, but in this study the survival data were evaluated until the day of transplantation.
Polymerase chain reaction (PCR) analysis of the FLT3/ITD
Genomic DNA was isolated from pellets of BM samples, such as cryopreserved mononuclear cells, paraffin-or plastic-embedded BM sections, or BM smear slides, at the time of diagnosis using an AccuPrep Genomic DNA Extraction Kit (Bioneer, Seoul, Korea) according to the manufacturer's protocol. PCR amplification of genomic DNA was carried out with the appropriate primers using the thermal cycler (PTC 200, MJ Research, Waltham, Mass, USA). A 328-bp fragment encompassing exon 14 and 15 of the wild-type FLT3 gene was amplified by genomic PCR using the primers 5'-CAATTTAGGTATGAAAGCC-3' (sense) and 5'-CTTTCAGCATTTTGACGGC AACC-3' (anti-sense). The reaction contained 2.5mm dNTP, 2.5mm MgCl2, 1×PCR buffer, 0.5μm of each primer, and 1U Taq. polymerase in a total volume of 20 μL. Samples were amplified using standard PCR con-ditions: 5-min initial denaturation at were resolved on 5% polyacrylamide gels using the MADGE system (MadgBio, Grantham and Southampton, UK), stained with ethidium bromide and photographed under ultraviolet light. FLT3/ITD was detected as an abnormal, longer product ( Fig. 1 ).
Statistical analysis
The response to initial therapy was evaluated after induction chemotherapy. According to the NCI criteria, 12) CR was defined as a normocellular BM containing less than 5% blasts and showing evidence of normal maturation of other BM elements; an absolute neutrophil count of 1.5×10 9 /L or more; a platelet count of 100×10 9 /L or more; no blasts in the peripheral blood; and no extramedullary leukemia. Overall survival (OS) was defined as the time from diagnosis to death or transplantation. Leukemic-free survival (LFS) was calculated as survival without relapse, death, or transplantation from the date of first CR. Cytogenetic features were classified according to the classification of the MRC AML 10 trial and the Southwest Oncology Group (SWOG) study. 13, 14) The favorable-risk group included patients with inv (16) or t (8;21) . Cytogenetics were defined as adverse if they included at least five unrelated abnormalities (complex karyotype) or one of the following abnormalities: 5, 7, del (5q), abnormal 3q, or t (9;22). An intermediate prognosis was assumed in the presence of either a normal karyotype or any other chromosomal change not encompassed by the favorable or adverse group.
Categorical data were compared for patients with and without FLT3/ITD by means of Fisher's exact test, and continuous variables were compared using the Mann-Whitney U test. OS and LFS were analyzed by means of Kaplan-Meier survival curve estimates and log-rank tests for comparison of differences in the distribution of survival for patients with and without FLT3/ITD. OS is defined for all patients in a trial, and measured from the date of diagnosis onto a study until death from any cause. For a patient who is not known to have died by the end of study follow-up, observation of OS is censored on the date he or she was last known to be alive. For a patient underwent allogeneic or autoloug stem cell transplantation, OS is censored on the date of transplantation.
LFS is defined only for patients who achieve CR, and is measured from the date of attaining the leukemia-free state until the date of AML relapse or death from any cause, whichever occurs first. For a patient who is not known to have relapsed or died by the end of study follow-up, observation of LFS is censored on the date of his or her last follow-up examination. For a patient underwent allogeneic or autoloug stem cell transplantation, LFS is censored on the date of transplantation.
Univariate and multivariate Cox's proportional-hazards models were used to analyze the influence of age, gender, leukocyte counts, and peripheral or BM blasts percentage, treatment protocol, and cytogenetics. A P value less than 0.05 was considered to be statistically significant; 95% confidence intervals are given. All statistical computations were performed using SPSS software version 12.0. (SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline characteristics of the FLT3/ITD + patients
The mean age of the 123 patients was 49.4 years (range, 16∼84 years). In the total group of 123 patients, 47 (38.2%) had an FLT3/ITD. Details of the presenting features of the FLT3/ITD-positive group are given in Table 1 . The presence of the mutation was not related to age (P=0. 19) or gender (P=0.50). The median peripheral blood (PB) leukocyte counts at diagnosis were increased in patients with FLT3/ITD (28.6×10 9 /L) compared with those in patients without FLT3/ ITD (11.0×10 9 /L). Pair-wise comparisons showed that this difference between patients with and without FLT3/ ITD was statistically significant (P= 0.04). In contrast, there was no difference between the two groups regarding the percentage of BM blasts (75% vs. 80%, P=0.74). There was also no significant difference regarding other clinical characteristics, such as hemoglobin level (P=0.93) or platelet count (P=0.67) at diagnosis.
Outcome of patients with FLT3/ITD
To analyze the response to or outcome of therapy, 90 patients who received intensive induction chemotherapy were evaluated. Median follow-up duration was 7.5 months (range, 0.2∼93.3 months). There was no significant difference between patients with and without FLT3/ITD according to the treatment protocols (P=0.85) ( Table 1) .
Of the 90 patients, 73 (81.1%) achieved CR. Univariate analysis showed that there was no difference in the response rate to induction chemotherapy between patients with and without FLT3/ITD (FLT3/ITD + 85.4% vs. FLT3/ITD 77.6%, P=0.35).
The proportion of patients who needed two rounds of induction chemotherapy to achieve complete remission was higher in patients with the FLT3/ITD than in patients without the mutation (23.9% vs. 13.3%, P=0.15).
With respect to the relapse rate according to the presence of FLT3/ITD, there was a significantly high- er relapse rate in FLT3/ITD + patients than in FLT3/ ITD patients (55.6% vs. 16.7%, P=0.01).
In addition, as shown in Fig. 2 , the presence of FLT3/ITD was also associated with a lower leukemic-free survival (LFS) rate in patients with normal karyotype (median duration of LFS, 7.9±2.1 months vs. not available, P=0.01). While the overall survival (OS) in these patients seemed to show a similar trend, there was no statistical significance (median duration of OS, 11.3±3.1 months vs. 17.7±0 months, P= 0.16).
In multivariate analyses with Cox proportional haz-ard model, FLT3/ITD was found to be an independent prognostic factor of LFS in AML patients with normal karyotype ( Table 2) .
DISCUSSION
The RTKs are classified based on the presence of five immunoglobulin-like domains, a JM domain and two domains that are separated by a kinase insert domain. The FLT3 RTK domains are activated by an allosteric dimerization process through binding with its natural ligand (FL). [15] [16] [17] FLT3 is normally ex-pressed on the surface of early bone marrow hematopoietic progenitor cells and has been demonstrated to have an important role in the survival and/or differentiation of multipotent stem cells. [15] [16] [17] Furthermore AML cells have been shown to express FLT3, and exogenous FL can enhance their survival and proliferative responsiveness. [15] [16] [17] The mechanisms by which this FLT3/ITD contributes to AML remain unclear. In experimental systems, the FLT3/ITD leads to ligand-independent FLT3 dimerization and constitutive activation of the TK domains via autophosphorylation. 5, 18, 19) This in turn appears to constitutively activate signal transducers and activators of transcription 5 and mitogen-acitvated protein kinase and introduces autonomous cell growth in cytokine-dependent cell lines. 6, 7, 20) Since Kiyoi et al. 21) first reported the clinical outcome of AML patients with FLT3/ITD, many studies have found that the presence of the mutation correlated with a poor prognosis for these patients. 4, 8, 9, 22) Those results are still a source of debate. Frohling et al. 23) grouped patients according to karyotype and showed that the presence of FLT3/ITD was related to shorter overall survival (OS) and leukemic free survival (LFS) in normal karyotype. This was a noteworthy study because patients with normal cytogenetics comprise a heterogeneous molecular group and the molecular differences were likely to correlate with prognosis. A previous study also suggested that FLT3/ITD was associated with a significant increase in the relapse rate rather than a decrease in the CR. Kottaridis et al. 4) reported that the presence of FLT3/ITD was the worst prognostic factor for CR duration and relapse-free survival, based on multivariate analysis. In the present study, the CR rate was not affected by the presence of FLT3/ITD (P=0.35), although there was a significant difference in the relapse rate and LFS between the two groups (P=0.01 and P=0.01, retrospectively).
In the previous study, there was a significant association between FLT3/ITD and leukocytosis, indicating that the presence of FLT3/ITD enhances biological proliferation. 24) In this study, patients with FLT3/ITD had higher leukocyte counts at diagnosis (P=0.04), but other known prognostic factors, such as BM blast percentage at diagnosis and age, were not associated with the presence of FLT3/ITD. Furthermore, according to multivariate analyses including these variables, FLT3/ITD was an independent prognostic factor in these patients (P=0.01).
In the present study, there are some limitations. First, recent studies have shown that overrepresentation of the ITD relative to the wild-type FLT allele was especially predictive of an adverse outcome. 4, 25) The present study did not demonstrate the FLT3 allele ratio in individual patients. To make the FLT3/ITD assessment truly semiquantitative, a previous study suggested that GeneScan analysis should be used at diagnosis for better prognostification. 25) Second, in the present study, 22 and 6 patients underwent allogeneic and autologous stem cell transplantations, retrospectively. Because the number of patients who underwent transplantation was too small to be analyzed, their survival data after transplantation were not assessed in the present study because of possible selection bias.
In conclusion, this study demonstrated that for AML patients with normal karyotype, the presence of the FLT3/ITD has important implications with respect to disease management. The assessment of this mutation allows the identification of those patients who have a probability of shorter LFS and higher rate of relapse, which may contribute to the stratification of treatment AML patients with normal karyotype. 
